2017 Sec 1 Green Book

FROM THE AMERICAN ACADEMY OF PEDIATRICS

55. Garbutt J, St Geme JW, III, May A, Storch GA, Shackelford PG. Developing community- speci fi c recommendations for fi rst-line treatment of acute otitis media: is high- dose amoxicillin necessary? Pediatrics . 2004;114(2):342 – 347 56. Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R. Susceptibilities of Haemo- philus in fl uenzae, Streptococcus pneumo- niae , including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother . 2009; 63(3):511 – 519 57. Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N. Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of far- openem. Antimicrob Agents Chemother . 2008;52(7):2639 – 2643 58. Jacobs MR, Good CE, Windau AR, et al. Ac- tivity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Che- mother . 2010;54(6):2716 – 2719 59. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus in fl uenzae. Clin Microbiol Rev . 2007;20(2): 368 – 389 60. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B. Risk factors for invasive pneumococcal disease in chil- dren: a population-based case-control study in North America. Pediatrics . 1999; 103(3). Available at: www.pediatrics.org/ cgi/content/full/103/3/e28 61. Seikel K, Shelton S, McCracken GH Jr. Middle ear fl uid concentrations of amox- icillin after large dosages in children with acute otitis media. Pediatr Infect Dis J . 1997;16(7):710 – 711 62. Cohen R, Navel M, Grunberg J, et al. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: clinical ef fi cacy and change in nasopharyngeal fl ora. Pediatr Infect Dis J . 1999;18(5):403 – 409 63. Green SM, Rothrock SG. Single-dose in- tramuscular ceftriaxone for acute otitis media in children. Pediatrics . 1993;91(1): 23 – 30 64. Leibovitz E, Piglansky L, Raiz S, Press J, Leiberman A, Dagan R. Bacteriologic and clinical ef fi cacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J . 2000;19(11): 1040 – 1045 65. DePestel DD, Benninger MS, Danziger L, et al. Cephalosporin use in treatment of

patients with penicillin allergies. J Am Pharm Assoc . 2008;48(4):530 – 540 66. Pichichero ME. A review of evidence sup- porting the American Academy of Pediat- rics recommendation for prescribing cephalosporin antibiotics for penicillin- allergic patients. Pediatrics . 2005;115(4): 1048 – 1057 67. Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin- allergic patients: a meta-analysis. Oto- laryngol Head Neck Surg . 2007;136(3): 340 – 347 68. Park MA, Koch CA, Klemawesch P, Joshi A, Li JT. Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol . 2010;153(3): 268 – 273 69. Jacobs MR. Antimicrobial-resistant Strep- tococcus pneumoniae: trends and man- agement. Expert Rev Anti Infect Ther . 2008; 6(5):619 – 635 70. Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis . 2012;54(8):e72 – e112 71. Brook I, Gober AE. Resistance to anti- microbials used for therapy of otitis media and sinusitis: effect of previous antimi- crobial therapy and smoking. Ann Otol Rhinol Laryngol . 1999;108(7 pt 1):645 – 647 72. Brook I, Gober AE. Antimicrobial re- sistance in the nasopharyngeal fl ora of children with acute maxillary sinusitis and maxillary sinusitis recurring after amoxicillin therapy. J Antimicrob Chemo- ther . 2004;53(2):399 – 402 73. Dohar J, Canton R, Cohen R, Farrell DJ, Felmingham D. Activity of telithromycin and comparators against bacterial pathogens isolated from 1,336 patients with clinically diagnosed acute sinusitis. Ann Clin Microbiol Antimicrob . 2004;3(3): 15 – 21 74. Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum PC. Susceptibili- ties of Streptococcus pneumoniae and Haemophilus in fl uenzae to 10 oral anti- microbial agents based on pharmacody- namic parameters: 1997 U.S. surveillance study. Antimicrob Agents Chemother . 1999;43(8):1901 – 1908 75. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired re- spiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother . 2003;52(2):229 – 246

43. Kristo A, Uhari M, Luotonen J, Ilkko E, Koivunen P, Alho OP. Cefuroxime axetil versus placebo for children with acute respiratory infection and imaging evi- dence of sinusitis: a randomized, con- trolled trial. Acta Paediatr . 2005;94(9): 1208 – 1213 44. Hoberman A, Paradise JL, Rockette HE, et al. Treatment of acute otitis media in children under 2 years of age. N Engl J Med . 2011;364(2):105 – 115 45. Tahtinen PA, Laine MK, Huovinen P, Jalava J, Ruuskanen O, Ruohola A. A placebo- controlled trial of antimicrobial treat- ment for acute otitis media. N Engl J Med . 2011;364(2):116 – 126 46. Gordts F, Abu Nasser I, Clement PA, Pierard D, Kaufman L. Bacteriology of the middle meatus in children. Int J Pediatr Otorhinolaryngol . 1999;48(2):163 – 167 47. Parsons DS, Wald ER. Otitis media and sinusitis: similar diseases. Otolaryngol Clin North Am . 1996;29(1):11 – 25 48. Revai K, Dobbs LA, Nair S, Patel JA, Grady JJ, Chonmaitree T. Incidence of acute oti- tis media and sinusitis complicating up- per respiratory tract infection: the effect of age. Pediatrics . 2007;119(6). Available at: www.pediatrics.org/cgi/content/full/119/6/ e1408 49. Klein JO, Bluestone CD. Textbook of Pedi- atric Infectious Diseases . 6th ed. Phila- delphia, PA: Saunders; 2009 50. Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J . 2010;29(4): 304 – 309 51. Brook I, Gober AE. Frequency of recovery of pathogens from the nasopharynx of children with acute maxillary sinusitis before and after the introduction of vac- cination with the 7-valent pneumococcal vaccine. Int J Pediatr Otorhinolaryngol . 2007;71(4):575 – 579 52. Wald ER. Microbiology of acute and chronic sinusitis in children. J Allergy Clin Immunol . 1992;90(3 pt 2):452 – 456 53. Centers for Disease Control and Pre- vention. Effects of new penicillin suscep- tibility breakpoints for Streptococcus pneumoniae — United States, 2006-2007. MMWR Morb Mortal Wkly Rep . 2008;57 (50):1353 – 1355 54. Centers for Disease Control and Preven- tion. Active Bacterial Core Surveillance (ABCs): Emerging Infections Program Net- work. 2011. Available at: www.cdc.gov/abcs/ reports- fi ndings/survreports/spneu09.html. Accessed November 6, 2012

PEDIATRICS Volume 132, Number 1, July 2013

113